Status:
UNKNOWN
A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease
Lead Sponsor:
Shanghai Mental Health Center
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-85 years
Phase:
NA
Brief Summary
The prevalence of Mild Cognitive Impairment (MCI) is about 15%-17%. 10%-15% of MCI progresses to Alzheimer's disease (AD) every year. The annual incidence of MCI in the normal elderly is about 1%. is ...
Eligibility Criteria
Inclusion
- 2011 NIA-AA criteria of MCI due to AD or AD
Exclusion
- Non AD dementia
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2022
Estimated Enrollment :
360 Patients enrolled
Trial Details
Trial ID
NCT04137926
Start Date
March 1 2020
End Date
November 30 2022
Last Update
September 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychogeriatrics，Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China, 200030